Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Clinical trial NCT07166419 · SUSPENDED

Trial details

NCT number: NCT07166419
Sponsor: Ohio State University Comprehensive Cancer Center
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive Recurrent Acute Lymphoblastic Leukemia Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive Recurrent Indolent Non-Hodgkin Lymphoma Recurrent Lymphoblastic Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Transformed Chronic Lymphocytic Leukemia Refractory Acute Lymphoblastic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive Refractory Indolent Non-Hodgkin Lymphoma

Start date: 2026-01-14
Primary completion: 2026-12-31
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.